Dilution Intelligence for Nasdaq & NYSE StocksShareStructure.io ↗

ShareStructure News

The Filing Desk · Sunday, November 22, 2026
← The Filing Desk

Co-Diagnostics Float Faces 2.2× Overhang From a Single Convertible Lender

A November 13 shareholder vote could unlock roughly 17.9 million conversion shares and authorize reverse splits totaling up to 1-for-750, reshaping a capital structure that has already expanded 335% in twelve months.

By ShareStructure Research Desk·

Co-Diagnostics, Inc. (NASDAQ: CODX) is drawing trader attention ahead of a special meeting that could fundamentally alter the molecular-diagnostics company's share structure. The single most important structural fact: one lender, J.J. Astor & Co., holds convertible notes whose potential conversion shares equal 2.2 times the entire public float.

The company currently has 8.82 million shares outstanding and an estimated tradeable float of about 8.0 million shares — calculated after removing 600,000 restricted commitment shares issued to Astor and roughly 134,000 insider-held shares. Those 8.82 million shares sit inside a 100-million-share authorized ceiling, leaving ample room for issuance without a charter amendment.

The Astor facility

In October 2026 CODX entered a senior secured installment convertible note with J.J. Astor, receiving $2.1 million in cash against $2.835 million in principal — a 1.35× factor rate, meaning the company owes 35% more than it received. The note is repaid in 30 weekly installments of $94,500. When Astor chooses to convert rather than accept cash, it does so at 90% of the lowest ten-day VWAP — a variable-rate discount that lets the lender pay less than the prevailing market price. After a default, that discount widens to 80%.

Today a conversion floor tied to Nasdaq's Minimum Price (roughly $1.09) limits how many shares Astor can extract. Proposal 7 on the November 13 ballot would slash that floor to about $0.218. At that level, the outstanding $2.55 million in principal converts into approximately 11.7 million shares. Add the optional $1.35 million Additional Note available from December 8, and total conversion shares reach roughly 17.9 million — dwarfing the 8.0-million-share float. The company's own proxy discloses that if the floor fell to par value ($0.001), up to 4.185 billion shares could theoretically be issued.

The ATM sweep

All proceeds from the company's at-market equity offering — a facility that lets it sell shares into the open market at prevailing prices through agent Maxim Group — are routed to a deposit account controlled by Astor. At approximately $0.40 per share, each $94,500 weekly payment requires the sale of about 236,000 new shares. That is the current dilution engine. Roughly 1.24 million ATM shares were sold from August through October.

Reverse-split authority

Proposal 8 asks shareholders to authorize the board to execute multiple reverse splits totaling up to 1-for-750, with the 100-million authorized share count unchanged afterward. A reverse split would consolidate the outstanding count while preserving the full authorized ceiling, mechanically reopening room for further issuance. CODX already executed a 1-for-30 reverse split in January 2026.

Secondary overhang

Armistice Capital and Orca Capital hold about 5.0 million warrants — contracts giving the right to buy shares — at exercise prices near $1.56. Those warrants are roughly four times out of the money, so near-term dilution risk from them is low. However, 3.4 million of those warrants become exercisable only if Proposal 6 passes on November 13, and they carry a Black-Scholes payout clause in a fundamental transaction and a reverse-split price reset.

Dilution trajectory

The share count has grown from about 2.03 million (split-adjusted, November 2025) to 8.82 million — a 335% increase in twelve months, fueled by eleven financing events through a single placement agent. Total pending shares across all instruments stand at roughly 23.0 million, representing 288% of the current float.

CODX carries a dilution risk score of 8 out of 10 — rated HIGH. The Nasdaq compliance panel's monitoring period expires on March 9, 2027; a bid below $1.00 for 30 consecutive business days before that date would trigger delisting with no additional cure period.

The Morning Brief · Free

The small-caps in play, before the open.

A free premarket dispatch from the ShareStructure News desk — the movers that matter, with the dilution read most traders miss.

Free · No spam · Unsubscribe anytime

ShareStructure provides algorithmic, data-driven analysis of public SEC filings and does not provide investment advice. ShareStructure receives no compensation from the companies it covers. An affiliated entity (Darrow Group) provides paid investor-relations services to some public companies; ShareStructure does not publish coverage of those companies while an engagement is active. Analysis is derived from primary-source filings and is not a recommendation to buy or sell any security.

Co-Diagnostics Float Faces 2.2× Overhang From a Single Convertible Lender — ShareStructure News